| 26.95 -0.55 (-2%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 36 | 1-year : | 39.7 |
| Resists | First : | 30.82 | Second : | 33.99 |
| Pivot price | 31.31 |
|||
| Supports | First : | 25.7 | Second : | 21.38 |
| MAs | MA(5) : | 29.93 |
MA(20) : | 31.56 |
| MA(100) : | 26.53  |
MA(250) : | 26.55 |
|
| MACD | MACD : | -0.6 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 32.2 |
| RSI | RSI(14): 32.3 |
|||
| 52-week | High : | 44.59 | Low : | 13.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZBIO ] has closed below the lower bollinger band by 10.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 39.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.56 - 28.73 | 28.73 - 28.86 |
| Low: | 25.52 - 25.73 | 25.73 - 25.89 |
| Close: | 26.66 - 26.99 | 26.99 - 27.22 |
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Wed, 23 Sep 2026
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn? - AlphaStreet
Wed, 23 Sep 2026
Zenas BioPharma (ZBIO) Could Be 44% Undervalued As New Shelf Filings Raise Dilution Questions - simplywall.st
Wed, 23 Sep 2026
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn? - Insider Monkey
Wed, 23 Sep 2026
Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves? - Yahoo Finance
Fri, 18 Sep 2026
Zenas BioPharma Grants Stock Options and RSUs to Newly Hired Employees as Inducement Awards - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 4.703e+007 (%) |
| Held by Institutions | 16.6 (%) |
| Shares Short | 12,170 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.7387e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 765.9 % |
| Return on Equity (ttm) | -34.5 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | -3.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.99 |
| Qtrly Earnings Growth | -9.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -226 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.166e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|